Loading
Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials.
Jean-Jacques Grob is professor of dermatology at Aix-Marseille University and a leader of the French and European melanoma trial groups. He was first author of the 2020 Journal of Clinical Oncology report of KEYNOTE-629, in which pembrolizumab produced durable responses in recurrent or metastatic cutaneous squamous-cell carcinoma, and a lead investigator on the COMBI-d, KEYNOTE-054 and CheckMate 238 melanoma trials.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma | Journal of Clinical Oncology | 2020 |
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types), Melanoma and the tags skin, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.